Laboratory of Human Carcinogenesis, Center of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Laboratory of Human Carcinogenesis, Center of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Trends Cancer. 2021 Jun;7(6):488-495. doi: 10.1016/j.trecan.2020.12.010. Epub 2021 Jan 11.
Comorbid chronic diseases affect cancer patients with an increasing frequency as populations get older. They negatively and disproportionately impact underserved populations and influence cancer diagnosis, tumor biology and metastasis, and choice of treatment. Many comorbidities are associated with a delayed cancer diagnosis. Although the relationship between comorbidities and cancer risk and survivorship has been studied extensively, we still lack knowledge on how they affect tumor biology and the metastatic process. Here, we will discuss our current understanding of mechanisms linking comorbidities to an adverse tumor biology and lethality and introduce thoughts of how we can close existing gaps in this knowledge. We argue that research into comorbidity-induced alterations in cancer metastasis, immunity, and metabolism should be prioritized.
随着人口老龄化，合并的慢性疾病越来越频繁地影响癌症患者。它们对服务不足的人群产生负面影响且不成比例，并影响癌症的诊断、肿瘤生物学和转移以及治疗的选择。许多合并症与癌症诊断的延迟有关。尽管已经广泛研究了合并症与癌症风险和生存之间的关系，但我们仍然缺乏关于它们如何影响肿瘤生物学和转移过程的知识。在这里，我们将讨论我们目前对将合并症与不良肿瘤生物学和致死率联系起来的机制的理解，并介绍我们如何缩小这方面知识差距的想法。我们认为，应该优先研究合并症引起的癌症转移、免疫和代谢改变。
